Gilead Sciences, Inc. (GILD.MX)
| Previous close | 1,121.00 |
| Open | 1,141.00 |
| Bid | 1,030.02 x 500000 |
| Ask | 1,185.00 x 300000 |
| Day's range | 1,121.00 - 1,121.00 |
| 52-week range | 1,121.00 - 1,486.00 |
| Volume | |
| Avg. volume | 221 |
| Market cap | 1.398T |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 181.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 52.67 (4.70%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
- Business Wire
Gilead Sciences Announces First Quarter 2024 Financial Results
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
